Study guide

7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics

Key Takeaways Explain This Topic AI

The blood-gas partition coefficient ( λ b / g \lambda_{b/g} λ b / g ​ ) is the primary determinant of induction and emergence speed; agents with low blood solubility (desflurane 0.42, sevoflurane 0.65) generate alveolar and arterial partial pressures rapidly, yielding fast wash-in ( F A / F I F_A/F_I F A ​ / F I ​ ), unlike soluble agents (isoflurane 1.4, halothane 2.4).

Desflurane's high saturated vapour pressure (88.5 kPa at 20°C) and boiling point near room temperature (22.8°C) necessitate a specialized heated (39°C) and pressurized (2 atm) Tec 6 vaporizer to prevent uncontrolled boiling and ensure accurate concentration delivery.

Increased alveolar ventilation accelerates F A / F I F_A/F_I F A ​ / F I ​ wash-in dramatically for soluble anaesthetics like isoflurane but has minimal impact on poorly soluble agents like desflurane, whereas increased cardiac output slows F A / F I F_A/F_I F A ​ / F I ​ rise by removing more agent from the alveoli into pulmonary venous blood.

The second-gas effect and concentrating effect occur when high-volume uptake of nitrous oxide concentrates co-administered volatile anaesthetics and augments tracheal inflow, while rapid nitrous oxide efflux upon cessation dilutes alveolar gases, causing diffusion hypoxia (Fink effect).

Last updated: October 2026

7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics

Inhalational anaesthesia depends on the precise thermodynamic delivery of volatile liquids via vaporizers into a breathing circuit, their alveolar uptake into pulmonary capillary blood, and their distribution across the blood-brain barrier to central nervous system target sites. Mastering the physical principles, solubility coefficients, and kinetic wash-in equations allows anaesthetists to control the depth and speed of general anaesthesia with millimetric precision.

1. Physical and Thermodynamic Properties of Inhalational Anaesthetics

At standard ambient room temperature and sea-level atmospheric pressure (101.3 kPa / 760 mmHg), modern volatile agents exist in the liquid state, whereas nitrous oxide exists as a gas.

Definitions of Core Thermodynamic Parameters

Saturated Vapour Pressure (SVP): The pressure exerted by the gas phase of a substance in dynamic equilibrium with its liquid phase within a closed container at a specified temperature. SVP is independent of atmospheric pressure and ambient volume; it depends solely on the chemical structure of the agent and the ambient temperature.

Boiling Point ( T b T_b T b ​ ): The temperature at which the saturated vapour pressure of the liquid equals the surrounding ambient atmospheric pressure. When ambient pressure decreases (e.g., at high altitude), boiling point decreases.

Latent Heat of Vaporization: The energy (calories or joules) required to convert 1 gram of liquid into vapour at constant temperature. As liquid vaporizes inside a vaporizer, it absorbs heat from the remaining liquid and surrounding metal, dropping the liquid temperature and lowering the SVP unless compensated thermally.

Volatile Agent Chemical Formula Molecular Weight (g/mol) Boiling Point (°C) SVP at 20°C (kPa / mmHg) SVP at 22°C (kPa / mmHg) Preservative / Container

Desflurane C F 3 − C H ( F ) − O − C H F 2 CF_3-CH(F)-O-CHF_2 C F 3 ​ − C H ( F ) − O − C H F 2 ​ 168.0 22.8 88.5 / 664 97.3 / 730 Pure liquid, aluminum bottle

Isoflurane C F 3 − C H C l − O − C H F 2 CF_3-CHCl-O-CHF_2 C F 3 ​ − C H Cl − O − C H F 2 ​ 184.5 48.5 32.0 / 238 35.0 / 262 Pure liquid, amber glass

Sevoflurane ( C F 3 ) 2 C H − O − C H 2 F (CF_3)_2CH-O-CH_2F ( C F 3 ​ ) 2 ​ C H − O − C H 2 ​ F 200.1 58.5 21.0 / 157 22.7 / 170 Water ( ≥ 300 ppm \ge 300\text{ ppm} ≥ 300 ppm ), PEN bottle

Halothane C F 3 − C H B r C l CF_3-CHBrCl C F 3 ​ − C H B r Cl 197.4 50.2 32.0 / 243 35.2 / 264 Thymol (0.01%), amber glass

Nitrous Oxide ( N 2 O N_2O N 2 ​ O ) N 2 O N_2O N 2 ​ O 44.0 -88.5 Gas at 20°C (Critical T T T : 36.5°C, Critical P P P : 72.4 bar) Gas (Liquid in tank at 50 bar) Stored as liquid-vapour mix in blue cylinder Vaporizer Engineering Comparison:

  • Variable-Bypass Vaporizers (Sevoflurane, Isoflurane) Tec 6 Heated Vaporizer (Desflurane)
  • Fresh gas splits: bypass vs vaporizing chamber - No splitting of fresh gas flow
  • Temperature compensation: bimetallic strip - Electrically heated to 39°C
  • Agent-specific keyed filler collars - Pressurized to 2 atm (1500 mmHg)
  • Relies on ambient vapor pressure - Pure desflurane vapor injected into FGF
  • The Desflurane Vaporizer Challenge: The Tec 6 Injector

Desflurane's boiling point (22.8°C at 1 atm) is remarkably close to standard ambient operating theatre temperatures (20-22°C). In an unheated variable-bypass vaporizer, slight environmental temperature elevations would cause desflurane to boil uncontrollably, producing massive cooling from the latent heat of vaporization, erratic vapour output, and potentially lethal anesthetic overdoses.

To overcome this, the Datex-Ohmeda Tec 6 (and Dräger D-Vapor) vaporizer is designed as an electrically heated, pressurized, gas-injection device:

It heats the desflurane sump to a thermostatically controlled 39°C , generating a constant internal saturated vapour pressure of approximately 2 atmospheres (~1500 mmHg / 200 kPa) .

Fresh gas flow does not enter the desflurane chamber. Instead, fresh gas flows through a fixed resistance where a differential pressure transducer measures incoming gas flow rate.

A microprocessor-controlled precision throttling valve modulates the injection of pure desflurane vapour directly into the fresh gas stream proportional to the dialed concentration and fresh gas flow.

Clinical Trap at Altitude: Variable-bypass vaporizers (sevoflurane, isoflurane) deliver a constant partial pressure of agent regardless of altitude; because atmospheric pressure is lower at high altitude, the delivered percentage increases, maintaining clinical depth. In contrast, the Tec 6 vaporizer injects a fixed percentage (volume fraction) of desflurane. At high altitude, where total ambient pressure is reduced, the delivered partial pressure of desflurane is significantly lower than dialed, resulting in unintended light anaesthesia unless the dialed concentration is mathematically increased ( Dialed % = Desired % × 760 mmHg Ambient Pressure \text{Dialed } \% = \frac{\text{Desired } \% \times 760\text{ mmHg}}{\text{Ambient Pressure}} Dialed % = Ambient Pressure Desired % × 760 mmHg ​ ).

2. Partition Coefficients and the Meyer-Overton Correlation

A partition coefficient ( λ \lambda λ ) is the distribution ratio of an anaesthetic between two immiscible phases at thermodynamic equilibrium (when the partial pressures in both phases are identical).

λ A / B = Concentration in Phase A Concentration in Phase B at equal partial pressure \lambda_{A/B} = \frac{\text{Concentration in Phase A}}{\text{Concentration in Phase B}} \quad \text{at equal partial pressure} λ A / B ​ = Concentration in Phase B Concentration in Phase A ​ at equal partial pressure

Volatile Agent Blood-Gas ( λ b / g \lambda_{b/g} λ b / g ​ ) Oil-Gas ( λ o / g \lambda_{o/g} λ o / g ​ ) Brain-Blood ( λ brain / b \lambda_{\text{brain}/b} λ brain / b ​ ) Fat-Blood ( λ fat / b \lambda_{\text{fat}/b} λ fat / b ​ )

  • Desflurane 0.42 19 1.3 27
  • Nitrous Oxide 0.47 1.4 1.1 2.3
  • Sevoflurane 0.65 47 1.7 48
  • Isoflurane 1.40 98 1.6 45
  • Halothane 2.40 224 2.9 60
  • Diethyl Ether 12.0 65 1.1 5.5
  • The Meyer-Overton Hypothesis and Lipid Solubility

The Meyer-Overton hypothesis states that the anaesthetic potency of an inhalational agent correlates directly with its lipid solubility, as quantified by its oil-gas partition coefficient ( λ o / g \lambda_{o/g} λ o / g ​ ): MAC × λ o / g ≈ Constant ≈ 1.3 (MAC expressed in atmospheres) \text{MAC} \times \lambda_{o/g} \approx \text{Constant} \approx 1.3\text{ (MAC expressed in atmospheres)} MAC × λ o / g ​ ≈ Constant ≈ 1.3 (MAC expressed in atmospheres)

Agents with high oil-gas solubility (e.g., halothane λ o / g = 224 \lambda_{o/g} = 224 λ o / g ​ = 224 , isoflurane λ o / g = 98 \lambda_{o/g} = 98 λ o / g ​ = 98 ) require very few molecules in the gas phase to achieve clinical immobility (low MAC: halothane 0.75%, isoflurane 1.15%).

Conversely, agents with low lipid solubility (e.g., desflurane λ o / g = 19 \lambda_{o/g} = 19 λ o / g ​ = 19 , nitrous oxide λ o / g = 1.4 \lambda_{o/g} = 1.4 λ o / g ​ = 1.4 ) have very high MAC values (desflurane 6.0%, N 2 O N_2O N 2 ​ O 104%).

Modern Molecular Reality: Anaesthetics do not produce immobility through non-specific physical expansion of membrane lipids (the historic "critical volume hypothesis"). Instead, the Meyer-Overton correlation reflects binding to specific hydrophobic cavities and amino acid pockets on ion channel proteins ( G A B A A GABA_A G A B A A ​ receptors, two-pore domain potassium channels like TREK and TASK, glycine receptors, and NMDA receptors).

3. Speed of Induction and Wash-In Dynamics: The F A / F I F_A/F_I F A ​ / F I ​ Ratio

General anaesthesia depth is governed strictly by the partial pressure of anaesthetic in brain tissue ( P brain P_{\text{brain}} P brain ​ ). Inhalational agents reach the brain across a continuous cascade of partial pressure gradients: Circuit Vapour ( P I ) ⟶ Alveolar Gas ( P A ) ⇌ Arterial Blood ( P a ) ⇌ Brain Tissue ( P brain ) \text{Circuit Vapour } (P_I) \longrightarrow \text{Alveolar Gas } (P_A) \rightleftharpoons \text{Arterial Blood } (P_a) \rightleftharpoons \text{Brain Tissue } (P_{\text{brain}}) Circuit Vapour ( P I ​ ) ⟶ Alveolar Gas ( P A ​ ) ⇌ Arterial Blood ( P a ​ ) ⇌ Brain Tissue ( P brain ​ )

Because arterial blood leaving pulmonary capillaries rapidly achieves partial pressure equilibrium with alveolar gas ( P a ≈ P A P_a \approx P_A P a ​ ≈ P A ​ ), and cerebral capillary blood equilibrates rapidly with brain tissue ( P a ≈ P brain P_a \approx P_{\text{brain}} P a ​ ≈ P brain ​ ), the rate of rise of alveolar concentration ( F A F_A F A ​ ) toward inspired concentration ( F I F_I F I ​ )—the F A / F I F_A/F_I F A ​ / F I ​ wash-in curve—is the universal determinant of induction speed . FA / FI Ratio

  • 1.0+============================================ N2O (0.47) & Desflurane (0.42)
  • | ....................... Sevoflurane (0.65)
  • 0.8| .....'
  • | ...''
  • 0.6| ..''
  • | .' Isoflurane (1.40)
  • 0.4| .'
  • | / Halothane (2.40)
  • 0.2|/__________________________________________
  • 0+-------------------------------------------->
  • 0 2 4 6 8 10 12 14 16 Time (Minutes)
  • Physiological Determinants Governing the F A / F I F_A/F_I F A ​ / F I ​ Ratio

Alveolar concentration represents a dynamic balance between delivery (input into alveoli via ventilation) and uptake (removal from alveoli into pulmonary capillary blood): Uptake = λ b / g × Q ˙ × ( P A − P v ) \text{Uptake} = \lambda_{b/g} \times \dot{Q} \times (P_A - P_v) Uptake = λ b / g ​ × Q ˙ ​ × ( P A ​ − P v ​ ) where λ b / g \lambda_{b/g} λ b / g ​ is blood-gas solubility, Q ˙ \dot{Q} Q ˙ ​ is cardiac output, and ( P A − P v ) (P_A - P_v) ( P A ​ − P v ​ ) is the alveolar-to-mixed venous partial pressure gradient.

Blood-Gas Partition Coefficient ( λ b / g \lambda_{b/g} λ b / g ​ ):

Blood acts as a pharmacological reservoir or "sponge".

Highly soluble agents (halothane 2.4, isoflurane 1.4) dissolve extensively into pulmonary blood. This rapid dissolution removes agent molecules from the gas phase, preventing the generation of gas partial pressure. Alveolar partial pressure ( P A P_A P A ​ ) rises sluggishly, resulting in a slow F A / F I F_A/F_I F A ​ / F I ​ rise and delayed induction .

Insoluble agents (desflurane 0.42, nitrous oxide 0.47, sevoflurane 0.65) have low blood capacity. Blood quickly saturates with minimal dissolved molecules, allowing P A P_A P A ​ to build rapidly. The F A / F I F_A/F_I F A ​ / F I ​ curve rises steeply, producing rapid induction and emergence .

Alveolar Ventilation ( V ˙ A \dot{V}_A V ˙ A ​ ):

Increased ventilation accelerates the delivery of fresh agent into the alveoli.

Hyperventilation has a profound accelerating effect on the F A / F I F_A/F_I F A ​ / F I ​ rise of soluble agents (halothane, isoflurane), because pulmonary uptake is massive and can be offset by increased replenishment.

Hyperventilation has minimal impact on insoluble agents (desflurane, N 2 O N_2O N 2 ​ O ), whose F A / F I F_A/F_I F A ​ / F I ​ ratio is already near ceiling.

Cardiac Output ( Q ˙ \dot{Q} Q ˙ ​ / Pulmonary Capillary Flow):

Increased cardiac output exposes more blood per minute to alveolar gas, augmenting uptake and carrying agent away into systemic tissues. This lowers alveolar partial pressure, slowing the rise of F A / F I F_A/F_I F A ​ / F I ​ .

In low cardiac output states (e.g., hemorrhagic shock, severe heart failure), decreased pulmonary flow lowers uptake, precipitating an alarmingly rapid surge in F A / F I F_A/F_I F A ​ / F I ​ , predisposing the patient to accidental volatile overdose.

Alveolar-to-Venous Partial Pressure Gradient ( P A − P v P_A - P_v P A ​ − P v ​ ):

At induction, mixed venous blood contains no anaesthetic ( P v = 0 P_v = 0 P v ​ = 0 ), so ( P A − P v ) (P_A - P_v) ( P A ​ − P v ​ ) is maximal, driving maximal uptake.

As the Vessel-Rich Group (VRG) tissues saturate and return drug via venous blood, P v P_v P v ​ rises. This narrows ( P A − P v ) (P_A - P_v) ( P A ​ − P v ​ ) , uptake decreases, and F A / F I F_A/F_I F A ​ / F I ​ approaches 1.0.

Functional Residual Capacity (FRC):

The FRC acts as an initial mixing chamber that dilutes inspired gas. A smaller FRC (infants, pregnancy, morbid obesity) allows faster alveolar wash-in and faster induction.

4. Kinetic Interactions: The Concentration Effect and Second-Gas Effect

When inhalational anaesthetics are administered in high concentrations, physical gas interactions accelerate alveolar wash-in beyond standard ventilation kinetics.

The Concentration Effect

Applies when a gas is delivered at high inspired fractions (e.g., 50-70% nitrous oxide). It comprises two distinct mechanisms:

The Concentrating Effect: The rapid uptake of huge volumes of N 2 O N_2O N 2 ​ O (up to 1000 mL/min initially) from the alveoli into pulmonary blood reduces the total volume of remaining alveolar gas. The unabsorbed gas molecules are compressed into a smaller alveolar volume, increasing their fractional concentration.

Augmented Tracheal Inflow: The rapid shrinkage of alveolar gas volume creates a transient sub-atmospheric alveolar pressure, drawing an additional volume of fresh gas from the breathing circuit into the lungs during inspiration.

The Second-Gas Effect

The second-gas effect is the practical extension of the concentration effect when two gases are administered simultaneously:

A high concentration of a rapidly absorbed primary gas (first gas, e.g., 70% N 2 O N_2O N 2 ​ O ) is administered alongside a low concentration of a potent volatile anaesthetic (second gas, e.g., 2% sevoflurane ).

The massive, rapid uptake of N 2 O N_2O N 2 ​ O shrinks alveolar volume and draws an extra volume of circuit gas containing sevoflurane and oxygen into the lungs.

Consequently, the rate of rise of the second gas's alveolar concentration ( F A / F I F_A/F_I F A ​ / F I ​ ) is significantly accelerated , producing faster induction than if the volatile agent were delivered in oxygen alone.

5. Emergence Dynamics and Gas Cavity Expansion Emergence Phase (Discontinuation of N2O):

  • Blood (High N2O tension) ========> Alveoli (Rapid N2O flooding)
  • |
  • v
  • Dilutes Alveolar O2 --> Diffusion Hypoxia
  • Dilutes Alveolar CO2 --> Decreased Respiratory Drive
  • Rescue: 100% O2 for 5-10 minutes
  • Diffusion Hypoxia (The Fink Effect)

Upon cessation of nitrous oxide anaesthesia, the partial pressure gradient reverses dramatically. Because nitrous oxide is 34 times more soluble in blood than nitrogen , massive volumes of N 2 O N_2O N 2 ​ O diffuse out of pulmonary capillary blood into the alveoli (up to 1-2 L/min during the first 5 minutes), far faster than nitrogen can dissolve into blood.

This massive influx of N 2 O N_2O N 2 ​ O into the alveoli:

Dilutes Alveolar Oxygen: Alveolar P A O 2 P_A O_2 P A ​ O 2 ​ drops precipitously, producing severe, acute arterial hypoxemia ( diffusion hypoxia or the Fink effect).

Dilutes Alveolar Carbon Dioxide: Alveolar P A C O 2 P_A CO_2 P A ​ C O 2 ​ falls, blunting medullary chemoreceptor drive and inducing central hypoventilation.

Prevention: Always ventilate the patient with 100% O 2 \text{O}_2 O 2 ​ for at least 5 to 10 minutes following the discontinuation of nitrous oxide.

Expansion of Closed Gas Cavities

Nitrous oxide's 34-fold greater blood solubility relative to nitrogen governs its behavior in gas-containing body spaces. When N 2 O N_2O N 2 ​ O enters blood, it diffuses into an air-filled cavity 34 times faster than nitrogen can diffuse out into blood:

Compliant Cavities (Volume Expansion): In non-rigid structures, the space rapidly expands. A pneumothorax can double in size within 10 minutes and triple within 30 minutes when exposed to 75% N 2 O N_2O N 2 ​ O . Obstructed bowel loops expand, compromising mucosal perfusion and impeding surgical closure.

Non-Compliant Cavities (Pressure Elevation): In enclosed rigid spaces, volume cannot expand, so pressure surges precipitously:

Middle Ear: Middle ear pressure can exceed 50 cmH 2 _2 2 ​ O, dislodging tympanic membrane grafts or ossicular prostheses.

Venous Air Embolism: Inadvertent vascular air bubbles expand exponentially, causing acute right ventricular outflow obstruction and cardiovascular collapse.

Intraocular Gas Bubbles: In patients who have received intraocular gas injections (sulfur hexafluoride [ S F 6 SF_6 S F 6 ​ ] or perfluoropropane [ C 3 F 8 C_3F_8 C 3 ​ F 8 ​ ]) for retinal detachment repair, N 2 O N_2O N 2 ​ O diffuses into the globe, causing catastrophic intraocular hypertension and central retinal artery occlusion with irreversible blindness. N 2 O N_2O N 2 ​ O must be avoided until the gas has been absorbed: roughly 2 weeks after S F 6 SF_6 S F 6 ​ and 6 to 8 weeks after C 3 F 8 C_3F_8 C 3 ​ F 8 ​ ; follow the ophthalmologist's instructions or the patient's warning wristband.